CARISMA THERAPEUTICS INC (CARM) Stock Price, Quote, News and Overview
NASDAQ:CARM - Nasdaq - US14216R1014 - Common Stock - Currency: USD
CARM Quote, Performance and Key Statistics
CARISMA THERAPEUTICS INC
NASDAQ:CARM (1/30/2025, 5:50:50 PM)
After market: 0.4703 -0.03 (-5.75%)0.499
-0.01 (-1.13%)
The current stock price of CARM is 0.499 USD. In the past month the price increased by 13.13%. In the past year, price decreased by -76.68%.
CARM Latest News, Press Releases and Analysis
Curious about the stocks that are showing activity after the closing bell on Wednesday?
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for...
Carisma Therapeutics Announces Changes to its Board of Directors
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
CARM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.34 | 310.40B | ||
| AMGN | AMGEN INC | 14.78 | 152.67B | ||
| GILD | GILEAD SCIENCES INC | 21.88 | 120.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 859.61 | 112.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.04 | 75.06B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.75B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.13B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.16B | ||
| NTRA | NATERA INC | N/A | 23.27B | ||
| BIIB | BIOGEN INC | 8.95 | 21.31B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.49B |
Related stock screener links
About CARM
Company Profile
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Philadelphia, Pennsylvania and currently employs 107 full-time employees. The company went IPO on 2014-02-06. The company is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Company Info
CARISMA THERAPEUTICS INC
3025 Market Street Ste 140
PHILADELPHIA PENNSYLVANIA US
Employees: 107
Company Website: https://sesenbio.com/
Investor Relations: https://ir.carismatx.com/
Phone: 16174448550
CARM FAQ
What is the stock price of CARM?
The current stock price of CARM is 0.499 USD.
What is the symbol for CARISMA THERAPEUTICS INC stock?
The exchange symbol of CARISMA THERAPEUTICS INC is CARM and it is listed on the Nasdaq exchange.
On which exchange is CARM stock listed?
CARM stock is listed on the Nasdaq exchange.
Is CARM a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CARM, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CARM.
Does CARM stock pay dividends?
CARM does not pay a dividend.
What is the Price/Earnings (PE) ratio of CARM?
CARM does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.56).
What is the Short Interest ratio of CARM stock?
The outstanding short interest for CARM is 1.81% of its float.
CARM Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CARM. When comparing the yearly performance of all stocks, CARM is a bad performer in the overall market: 97.96% of all stocks are doing better.
CARM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CARM. CARM may be in some trouble as it scores bad on both profitability and health.
CARM Financial Highlights
Over the last trailing twelve months CARM reported a non-GAAP Earnings per Share(EPS) of -1.56. The EPS increased by 58.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -151.7% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CARM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to CARM. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 64.73% and a revenue growth 58.08% for CARM